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Abstract
Background: Guidelines suggest the patient community should be consulted from the 
outset when designing and implementing basic biomedical research, but such patient 
communities may include conflicting views. We examined how engagement occurred 
in one such instance.
Objective: Our objective was to scrutinize patient and public involvement (PPI) by a 
pan- European biomedical consortium working to develop drugs to treat autism. We 
aimed to use this as an example to illustrate how PPI has been utilized in biomedical 
research.
Setting, participants and analysis: Two public events, one in the UK and one in 
Denmark were conducted as part of the consortium’s on- going PPI activities in 2014 
and 2015. Sixty- six individuals submitted written comments on the consortium’s re-
search after these events. The textual data produced were analysed using a thematic 
approach. Approximately 71% of respondents reported themselves to be adults on the 
autism spectrum or parents of children with autism.
Results: The themes identified illustrated major differences between some community 
concerns and the biomedical research agenda. While treating autism per se. was seen 
as problematic by some, treating specific co- occurring problems was seen as helpful in 
some circumstances. The biomedical consortium selected PPI with a limited user view-
point at its outset and more widely once basic research was on- going.
Discussion: This case illustrates what we term “selective PPI” where only a sympa-
thetic and/or limited patient viewpoint is included. Findings highlight the perils of 
using selective PPI to legitimise scientific endeavours, and the possibilities for con-
structive dialogue.
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1  | INTRODUCTION
While there is much research on engagement with patient commu-
nities in health services and clinical research, less attention has been 
paid to the role of patients in shaping biomedical research agendas.1 
Patient and carer engagements are recognized as an important com-
ponent of drug development and implementation. Patient and public 
involvement (PPI) aims to improve the quality and responsiveness of 
biomedical research to public expectations and needs, and to influ-
ence clinical guidelines.2 PPI is now a central feature of biomedical 
research applications and is required by funding programmes.3 The 
rise of PPI as a central tenet of biomedical research has been sup-
ported by social science research pointing to the value of lay- expertise 
and local knowledge situated in context and experience.4,5 Patients 
should be involved in biomedical research development for ethical, 
political, and pragmatic reasons: In the first case, it is the moral right 
of patients to influence discussions that will affect their lives; in the 
second, the accountability of public money is at stake; and in the third, 
lay- knowledge can improve translation of interventions to user com-
munities more effectively.6 PPI is encouraged at every stage, from 
generation of research questions through to dissemination, so that 
basic biomedical research can translate into what is useful to, accessi-
ble to, and welcomed by patient communities.
Despite this policy directive to address patient concerns from the 
outset,7 the evidence that publics and patients are involved in biomed-
ical research is mixed.8 Researchers themselves sometimes view PPI 
as something they are required to do in order to fulfil funding guide-
line requirements: PPI is seen as a “tickbox” exercise for some in bio-
medical industry and academia.9 One qualitative study found patients’ 
perspectives were excluded during meetings with experts, even when 
inclusion strategies were put in place.10 Here, we examine an instance 
of PPI in biomedical research (centred on the development of pharma-
cological treatments for autism) to illustrate how PPI has been utilized.
Autism is a good example of a health condition that has inspired a 
huge amount of community, political and social activism over many de-
cades.11 Many in the autism community feel they are not listened to by 
the research community, even when their views are solicited.12 Within 
the context of autism activism, the subject of a “cure” for autism has 
received a good deal of attention and divided community opinion. 
Two key activist viewpoints regarding a cure for autism have been de-
scribed in polarized terms as: (i) a pro- cure stance (mainly represented 
by biomedical researchers and some charities); and (ii) an anticure 
stance (mainly represented by adults with autism and some parents).13
Many autistic adults promote efforts to provide accommodations 
to remove specific obstacles for individuals with autism, but decry 
efforts to develop “cures.” These members of the autism community 
oppose elimination of autistic traits or symptoms.14 Their groups often 
deploy ideas of the disability rights movement especially the emerging 
neurodiversity movement, which sees autism and other neurodevelop-
mental disorders as a natural part of human variation, rather than a dis-
order. The movement is informed by the social model of disability that 
has traditionally separated personal impairment from disabling aspects 
of society.15 Here, disability is regarded as an emergent characteristic 
of individual differences encountering inaccessible or discriminatory 
social environments.16 Thus, the onus falls on society to change; that 
is, to embrace and accept autistic traits and behaviours, and act to ac-
commodate them, rather than target individuals with autism for “cure.” 
In a thoughtful analysis of online discussions, Brownlow has described 
how individuals with autism are constructed by medicine as needing 
to change (via intervention and treatment) in order to accommodate 
the non- autistic world.17
The subject of autism treatments has received less discussion 
than the more provocative and dichotomous subject of autism cure. 
Numerous groups around the world are conducting research in the 
biological substrates of autism, in a stated effort to develop more ef-
fective treatments.18 Clinicians and biomedical researchers anticipate 
that basic biomedical research encompassing genetics and neurosci-
ence may eventually lead to new and more effective drug treatments 
for autism.19 The goal of autism treatment, according to medical 
professionals, is to improve communication, social, adaptive, and be-
havioural skills which constitute the core symptoms of autism.20
Autism treatment development is backed by relatives’ collectives 
and charities, including Autism Speaks, who argue that, “medicines for 
treating the three core symptoms of autism – communication difficul-
ties, social challenges and repetitive behavior – have long represented 
a huge area of unmet need”.21 Charities in the USA are the leading 
private funder of biomedical research in autism treatments; the charity 
Cure Autism Now provided more than $39 million for research grants 
before merging with Autism Speaks. Within the protreatment commu-
nity, parents of younger and severely affected children speak passion-
ately of the importance of efforts to develop biomedical treatment for 
what they see as a highly impairing and distressing condition.22 There 
is currently insufficient evidence to evaluate the benefits or adverse 
effects for pharmaceutical treatments for autism,23 and pharmacolog-
ical interventions are not currently recommended by national or inter-
national guidelines.24
As is evident from this overview, the autism community should 
not be considered as one homogenous voice, just as the public cannot 
be considered to share the same views. Within the autism community 
there are multiple “publics”25: small groups of people who follow a 
particular issue in detail. They are well informed about the issues and 
have very strong opinions on them. Given the necessity of PPI in basic 
biomedical research, it is important to establish what is and what is 
not acceptable to the various factions in the autism community re-
garding drug development, particularly given that at time of writing 
there were over 40 on- going clinical intervention trials registered 
with the US National Institute of Health testing drugs to treat au-
tism (Clinical trials.gov). As the trend to diagnose more children with 
autism continues, developing a pharmaceutical treatment for core 
autism symptoms in childhood could become an attractive target for 
further pharmacological industry investment. We were interested in 
how opinions on drug treatment varied in the autism community and 
whether the biomedical consortium had involved different patient and 
public opinion in its decision making. Our research questions were (i) 
what were patient and community views concerning development of 
pharmacological treatment for autism, and (ii) to what extent were 
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these taken into account by the biomedical scientists in shaping their 
research agenda?
2  | METHODS
2.1 | Background
In 2012, a large pan- European consortium, known as EU- AIMS, was 
funded to contribute understanding of underpinning biological mech-
anisms of autism and to leverage this knowledge to develop effective 
pharmacological and other interventions for autism. PPI was woven 
into consortium activities from the start, with a parent- run charity 
that is a known supporter of treatment of autism (Autism Speaks) as 
a co- applicant on the grant. The consortium has an independent eth-
ics advisory board (EAB), of which most of the authors are members.
In 2014 and 2015, the EAB convened two public events, one in 
London in the UK and one in Aarhus in Denmark. Both events were ad-
vertised widely via Universities and EAB networks, and via networks in 
the autism community.
During these two events, a promotional video was used as a 
prompt to solicit comments about the consortium project agenda. The 
video is freely available online, accessible at the bottom of the front 
page of the EU- AIMS website, branded “EU- AIMS project—What is 
EU- AIMS doing for autism research?”.26 A transcript of this video is 
available in the supporting material (Video S1). The video consists of 
interviews with prominent scientists working on individual biomedical 
studies that make up the consortium. These are upstream research 
projects focussed on discovering biological predispositions to autism 
and turning this knowledge into treatments. Primary areas of investi-
gation include genetic markers of autism, mouse models, and brain- 
based biomarkers. The video describes the ultimate aim of the project 
as being the effective harnessing of these approaches towards the 
production of pharmacological treatments for autism. Our aim was to 
assess diversity of community views to illustrate how PPI was used 
in the biomedical context. We analysed these data and report the 
extent to which community feedback was taken into account by the 
consortium.
2.2 | Data collection
The video was used as a prompt to solicit comments (our data) about 
the research agenda. Data were collected in 2 waves. Wave 1 was after 
the public events in 2015, EU-AIMS where a call for open comments 
on the video was made at the PPI events themselves. Wave 1 data 
were collected through emailing everyone who had left contact details 
at or before the events, inviting them to submit open comments about 
the video prompt. This included an autism charity that attended, and 
three autism groups. Wave 2 data were collected after a request from 
the consortium was made to diversify the sample (after comments 
that the sample was biased towards cognitively able self- advocates). 
As qualitative data, the responses represent a snapshot of opinion of 
a mobilized group from within the autism community, and we do not 
claim that this group is representative of the autism community as a 
whole. Nevertheless, a second wave of data collection took place in 
2016, via a free- response online survey. This was intended to diver-
sify the initial sample, albeit within the constraints of a qualitative sur-
vey. The free- response survey was linked from the EU- AIMS cohort 
Facebook page, and linked to the video prompt which was hosted by 
the EU- AIMS website. The online survey is available as supporting ma-
terial. Seven additional responses were obtained at wave 2.
These activities generated a data set consisting of approximately 
forty pages of written comments on the video prompt, from 66 indi-
vidual respondents. We asked respondents to report their relationship 
to autism and classified them as either having a diagnosis themselves, 
being a family member of a person with autism, having a professional 
interest or without any relationship. As most respondents who de-
clared this information had autism themselves, were directly related 
to a person with autism, or worked with children or adults with autism, 
we refer to the sample as “the autism community.”
2.3 | Ethics
Ethical approval for this study was given by the University of Exeter 
Ethics Committee at the school of social sciences: approval reference: 
201516- 063. Contributors who submitted comments were provided 
with an information sheet about the current study detailing its ration-
ale, and how their contributions would be reported. All respondents 
quoted and analysed here gave their explicit consent for their contri-
butions to be included after reading this information.
2.4 | Analysis
Data were analysed using a thematic approach to identify the signifi-
cance of patterns and their broader meaning. The method is described 
in detail elsewhere.27,28 First, two researchers familiarized themselves 
with the data by reading and rereading the initial data set and not-
ing early ideas. Second, preliminary codes were generated from cata-
loguing use of certain words and descriptive phrases in the context of 
the intended meaning across the entire data set. The original words 
used in the data were used to define the meaning of each code. Thus, 
the coding phase retained the original meaning as much as possible. 
Codes were cross- checked between two researchers, and a coding 
frame was agreed. The complete data set was then coded using NVivo 
software.
Codes were collated into potential themes, gathering all data under 
each code relevant to each putative theme. Themes were reviewed to 
check they made sense in relation to the coded extracts and with the 
entire dataset. Counter examples to the overall narrative were coded 
and included. Finally, appropriate quotes were selected to reflect the 
overall interpretation in the analysis.
3  | RESULTS
The participants’ relationship to autism was declared in the bulk of 
cases (n = 41). Of these, around half n = 20 (49%) were adults with 
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autism, 9 (22%) were family members of people with autism (almost 
all were parents), and 8 (19%) were involved with autism in a pro-
fessional capacity, for example teachers, clinicians, researchers and 
nurses. Most respondents were critical, probably because people who 
were motivated to respond did so to question the status quo on the 
development of drugs for autism. The two major themes identified are 
outlined below.
3.1 | Theme 1: autism is not a suitable target for 
drug treatment
The promotional video described autism as a “disease,” which pro-
voked a strong negative reaction from many respondents. Many 
were uneasy with autism being described as having a biological cause, 
pointing out there were diverse developmental pathways to autistic 
phenotypes, including “the attitudes of other humans.” Respondents 
thought that a disease label for autism was wrong:
It (the video) made autism sound entirely negative, like a 
disease. 
Autistic adult A
What on earth is Professor X doing calling autism a ‘dis-
ease’? It’s not a disease. 
Family member A
Analysis from the USA shows the majority of funding for autism 
research is currently for basic biomedical research.29 But autism, it was 
argued, was not suitable for pharmacological treatment in the same way 
as a short- term disease such as pneumonia, as “curing” was equated with 
changing somebody’s identity.
Autism is such an inseparable part of our identity, and 
eliminating it (if that is even possible) would mean elimi-
nating the individual. 
Autistic adult C
The heterogeneity of the condition and its nature as a spectrum “en-
compassing both the severely disabled and remarkably gifted” (in some 
cases a person may be both) led participants to question whether one 
treatment for all individuals was desirable or possible.
To what extent is it possible to talk in global terms about 
treating autism, given the wide heterogeneity of the con-
dition and given the existence of disparate comorbidities? 
Parent A
Overall, many participants were sceptical about drug development, 
questioning whether and in what ways treating autism with pills would 
enable children and adults to flourish.
Are some scientists trying to “make” certain types of 
human beings by eliminating parts they don’t like? Who 
will decide on the “treatment” if/when it is put in place; 
will it be doctors, parents/carers or autistic people 
themselves?
By “eliminating” autism or autistic traits we are losing a lot 
of important and useful features that these traits contain. 
Autistic adult D
Participants clearly adopted narratives of the neurodiversity 
movement that are directly related to social models of disability, but 
viewpoints were often nuanced with recognition of both strengths and 
challenges. It was acknowledged that people with autism might need 
help and support, but many also recognized advantages of autism that 
were in danger of being lost should a drug treatment be prescribed. 
Given these nuances, there was a strong resistance to the idea of 
“blanket approach” drug treatment, particularly from  autistic individ-
uals themselves.
I think the use of drugs to eliminate autism would be a ter-
rible idea, as it would eliminate large parts of the person’s 
character and if done on a large scale, would make the 
world a poorer and less diverse place. 
Autistic adult E
A mother wrote about her son who had severe autism at age three, 
but celebrated his later achievements (as an adult). She noted how ap-
preciating his adult accomplishments might not have been possible had 
drugs been prescribed when he was small, because treatment might 
have dampened some of his autistic traits:
If his doctor had said at the time that a drug was available 
to make him more sociable and make him like other chil-
dren, and if his doctor had recommended we try this drug, 
I would probably have done so. In hindsight, I am enor-
mously glad that such a drug was not available. 
Parent D
The point was that autistic traits could not be treated in isolation. If 
challenging aspects of autism were treated, this could result in the loss 
of valuable aspects too, throwing the baby out with the bathwater, so 
to speak.
In contrast to these views, some parents of severely affected 
children were in agreement with the message that autism can be 
considered akin to a disease that is harmful. A number of parents 
expressed forceful support for the drug development programme. 
These parents thought that, if there were drugs available, they 
would be used in combination with existing behavioural thera-
pies and that this would improve their children’s lives and provide 
needed support. One parent described his hopes for treating his 
son who was diagnosed with infantile autism:
If my son could take a pill for his autism and thus get rid 
of all the problems he contends with and is going to fight 
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with, I would almost force- feed him with such a pill! I can-
not understand the desire to ‘protect’ a handicap for hand-
icap’s sake! 
Parent B
These voices were reminiscent of those of parents of younger and 
severely affected children elsewhere who have spoken fervently about 
the significant need for research to develop biomedical treatments for 
what is, for them, an extremely damaging and demanding disorder.22 
Most comments that were supportive of drug development came 
from parents of young and severely affected children suggesting this 
group are more likely to be end users of a pharmacological treatment.
3.2 | Theme 2: circumstances when drug treatment 
is acceptable
Circumstances under which drugs would be acceptable and/or wel-
comed were described by some adults who were themselves on the 
autism spectrum. These involved short- term gains, and control by the 
person taking the drug, and did not involve “autism” as a generic target.
Agency was an important subtheme of drug treatment accept-
ability. Many participants stated it would be acceptable to treat if 
the individuals wanted it, and the person him/herself was able to 
control how, when and why the dose was administered. If the indi-
vidual was coerced or did not wish to be treated, it was unaccept-
able to administer a drug. Simply put, “you should not treat someone 
who does not want to be treated.” Control and agency, it was noted, 
are particularly difficult to achieve in the case of individuals with 
an intellectual disability or in those who are minors, and this led 
to heightened concerns about enforced treatment in these cases. 
Some respondents asked the question: “who decides”? in the event 
of an anti- autism drug coming to market. Participants were worried 
about who would determine when treatment should be adminis-
tered, to whom treatment should be administered, as well as when 
it would be deemed a success.
How do researchers decide when a child should be given 
medication and if it will be in the child’s best interests? 
Parent C
Respondents went beyond critique of biomedical research prior-
ities to question whether the products of research would translate 
into ethical clinical and societal practices. The use of psychotropics 
as a convenient form of social control, to suppress difficult or un-
wanted behaviours, was a concern. A Swedish study found autistic 
adults’ own agency was needed to render intervention meaningful to 
them.30 Other participants pointed out that drugs might be used as 
a matter of convenience, due to a combination of time pressures on 
clinicians and parents. One mother illustrated how she felt the mix of 
medical advice and time- pressure had led to a prescription culture.
When my son was a child and adolescent, a lot of his be-
haviours were attributed to his autism, when ..he was in 
excruciating pain from several debilitating medical condi-
tions. ….The point is, I am very worried that if there were 
blanket drug treatments for autism, he would have been 
put on these, which would have been a completely inap-
propriate red herring...   If blanket drugs become available, 
I imagine clinicians - hard-pressed, busy, overworked etc 
- will automatically reach for the prescription pad, rather 
than exploring more fully what the underlying issues are. 
Parent D
Two participants expressed concerns over the involvement of 
pharmaceutical companies, suggesting this could lead to publication 
bias towards positive findings, or become a market- driven process 
where the ultimate aim was to sell as much of the pharmacological 
product as possible.
By contrast, some autistic adults saw a drug as a potentially use-
ful tool to be used as required to manage stressful situations, or a 
way to deal with co- occurring problems such as anxiety, epilepsy, 
or other forms of distress. One adult with autism gave six specific 
examples of when and how drugs might be helpful, but only in the 
case where the person could decide when and how much of the drug 
was taken. This is one of her suggestions:
A way of “knocking one’s system into gear” when immo-
bilised – something like a piece of nicotine gum or a cup 
of strong coffee or some dextrasol, but specific enough to 
take on autistic stuckness. This would need to be very easy 
to access at all times. 
Autistic Adult E
Finally, there was a call for greater involvement of the autism 
community in future biomedical research. The charity Autism Speaks 
also came in for criticism, with autism community members ques-
tioning its “alarmist rhetoric,” and the lack of representation of peo-
ple with autism among employees and on the Board of Trustees. 
Overall it was clear there was more work to be done by the research 
community in terms of community engagement: “There needs to be 
greater involvement of the autism community in targeting resources 
to the critical needs of people with autism and their families, and in 
translating research into practice,” as one parent put it.
To summarize, respondents had a diverse range of opinions, 
ranging from those who raised concerns about biomedical research 
effort to drive the development of drugs, and its fundamental as-
sumption of the need for treatment and how this positioned au-
tistic individuals, whilst others wrote about the circumstances 
where drugs would be acceptable and/or welcome for them, 
through to a small group of enthusiastic advocates of the biomedi-
cal research. Respondents also wrote about concerns over the use 
of drugs in practice, and the importance of including a range of 
patient views.
A summarized list of the respondents’ comments was submitted 
to the consortium in 2015, and presented at a consortium meeting 
in 2016. The consortium decided to publish written replies to this 
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material on its website. At the time of writing (summer 2017), publi-
cation of these replies drafted by members of the consortium scien-
tific community had stalled, however the EAB had filmed a series of 
interviews with members of the consortium addressing community 
views, which the scientists addressed seriously and in good faith. 
The consortium agreed to feature the film on their website going 
forwards.
4  | DISCUSSION
The findings show the autism community is an example of a patient 
community which holds diverse opinions about the promises and per-
ils of biomedical research. Biomedical researchers initially selected 
community voices that were known to support their agenda (to de-
velop drugs to treat autism) when developing their grant, through a 
partner Autism charity which itself funds drug development. At that 
time, the consortium did not engage with those members of the com-
munity that did not share these views. Our findings led us to define 
and illustrate the concept of Selective PPI, where only a sympathetic 
and/or limited patient viewpoint is included. The analysis demon-
strates the need for major biomedical research projects to consider 
whether their PPI strategy might be selectively co- opting community 
voices that uncritically support a biomedical agenda. Below, we con-
sider the mismatches that acted as barriers to meaningful patient and 
public involvement in this case.
4.1 | Barriers to participation: mismatches
In their 1998 review of the PPI literature in health research, Grant- 
Pearce, Miles & Hills define “mismatches” as differences or disagree-
ments in perception, opinion, view or practical decision concerning 
the problem or needs to be addressed by research. They noted that 
these mismatches were under- recorded, and that very few studies in 
their review were able to draw direct comparisons between priorities 
of patient groups and professionals.
One mismatch exposed in our study was due to different ways 
“autism” was constructed by different actors, in line with their own 
agendas. In particular, there was tension between a “medical” vs a “so-
cial” model of autism. These models represent polarized perspectives 
on how autism is experienced and understood across different cultural 
contexts.31 Millions of dollars in funding and investment have been 
based on the biomedical narrative of autism.29 Social scientists have 
noted interventions unintentionally but intrinsically cast target be-
haviours as undesirable32,33 (a point applicable to all forms of childhood 
behaviour that are deemed treatable, for example, inattention and hy-
peractivity in ADHD34). The video prompt utilized a medical model to 
cast autism as a disease; that is, as a discrete and undesired entity 
separate from the individual. Pharmacological intervention promised 
to decrease the suffering caused by disease. However, many respon-
dents in our study, particularly adults with autism, viewed autism as 
an identity. These respondents questioned the implicit paternalism in 
autism intervention, arguing that intervention should not be assumed 
to be necessary. Thus, the video unwittingly created a barrier between 
the research consortium and the autism community by assuming that 
intervention was required for people with autism; by objectifying au-
tism as an entity apart from the person; and by commodifying the con-
tributions of autism research participants in an (identity- destroying) 
pharmacological product, all recognized as barriers to participation in 
autism research.35
A second mismatch was one of timing. As a collaboration between 
the Innovative Medicines initiative (IMI), the European Commission 
(EC) and the consortium institutions, EU- AIMS had an obligation to in-
clude PPI in the research project. PPI guidelines36 stress that research-
ers should involve users from the outset of the research. As noted 
above, the charity Autism Speaks was included as a formal collabora-
tor on the project; it has helped to identify research priorities, and it 
had membership on the consortium advisory team. However, Autism 
Speaks represents a particular view on biological treatments for autism 
(strongly in favour) that is not shared by others in the autism commu-
nity. Where there are intracommunity patient debates, certain posi-
tions may be co- opted to support a particular research agenda. When 
the consortium first presented the research project to the broader au-
tism community, and put up the video, was about 2 years into a 5- year 
research project. Thus, there was a mismatch in the timing of the start 
of the research project and the timing of the broader autism commu-
nity’s invited engagement. By the time of our community survey, the 
biomedical consortium was already committed to pre- specified work 
to target behaviours listed as core autism symptoms by agreement 
with funders. Thus, the later PPI was rendered “toothless” in that the 
biomedical research agenda was already set. The biomedical scientists’ 
responses were promised, but this process was stalled several times: 
at this point community concerns appeared to be seen as obstacles 
to be navigated, rather than utilizing them to set a research agenda. 
Addressing community antipathy may require careful coproduction 
from the outset.37,38
We therefore argue that the involvement of the charity Autism 
Speaks as the sole representative of the autism community in the 
research consortium is a case of “selective PPI,” in which PPI guide-
lines were followed by the biomedical consortium to the letter,36 but 
in a way that involved only those community voices that supported 
the consortium’s research agenda. While the involvement of Autism 
Speaks gave the research endeavour PPI direction and legitimacy at 
the point of submission for funding, it also ensured that, once the 
more critical voices of the broader autism community were engaged, 
their views would not alter the research agenda.
It is worth considering what “inclusive PPI” would have meant for 
the consortium research, and who is responsible for ensuring that inclu-
sive PPI is undertaken prior to submission for funding. While the pro-
ject protocol was still under construction. Inclusive PPI would almost 
certainly have prolonged the development of a highly complex, multi-
national research project. In large research consortia, pre- submission 
negotiations among researchers and with funders and industry require 
upfront investment of time and resources. The infrastructure of bio-
medical funding does not require a range of patient views, just pa-
tients’ views. It is not clear who should take responsibility for ensuring 
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an inclusive PPI process at this point in the research cycle; however, 
we do not believe that the responsibility rests with the biomedical re-
searchers alone. PPI is a higher- level mandate sent down from funders 
and policymakers, but it not part of the core business of most research-
ers. Moreover, the increasing emphasis on industry- academic partner-
ships in research pulls against inclusive PPI. The expectation of a viable 
commercial product to justify investment means that, in some cases, 
arguments against research that would produce such a product will 
be marginalized. Of course, this does not mean that such arguments 
should not be heard in the first place, nor does it mean that such argu-
ments should play no role in shaping the research protocol.
Selective PPI is enabled because, despite the rhetorical empha-
sis currently placed on PPI in research, there is no identified role in 
a biomedical project team in which responsibility for fair, just and in-
clusive PPI from the start of the research cycle resides. PPI plans are 
also not routinely reviewed by an independent PPI expert following 
submission of the grant. The responsibilities—for insisting on a PPI role 
from the outset of project development and an independent expert 
review of the PPI plan—rest with funders. As research funding proce-
dures are dominated by academics, and funding is based on scientific 
criteria, with biomedical research plans specified at the outset, is it 
surprising that many biomedical scientists currently see PPI as a tick 
box exercise? Arguably too, if inclusive PPI is a higher- level mandate, 
there should be a great deal more useful and structured training for 
researchers, training that includes analysis of mismatches and conflicts 
such as the ones identified here.
5  | CONCLUSION
The findings stress the importance of involving a range of patient 
views in research from the outset: from the generation of an idea 
through to research design and use of any outputs in the clinic and 
community. This is seen as a moral obligation to ensure that biomedi-
cal research addresses the needs of the user and carer communities, 
as research translates from bench to bedside.39 Thus users or patients 
are accorded “privileged knowledge”—a person carries more epistemic 
authority because they are from a certain group. Our case study raises 
the question of how PPI should take into account contrasting posi-
tions from within this patient community. It highlights what others 
have noted: that current strategies for patient participation in biomed-
ical research decision making are not effective.1 It also highlights the 
practical moral perils of using what we call “selective PPI” to legitimise 
scientific endeavours; and the enormous challenges of properly taking 
the views of a heterogeneous community into account within an inter-
national research portfolio that involves multiple funders, institutions 
and organizations.
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